Related Experiment Video
Updated: Aug 15, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Technology insight: Applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated
Rajiv Khanna1, Denis Moss, Maher Gandhi
1Tumour Immunology Laboratory, Queensland Institute of Medical Research, Queensland, Australia. rajivK@qimr.edu.au
Abstract:
The Epstein-Barr virus (EBV) is uniquely associated with a broad range of human malignancies. In spite of their diverse cellular origin, most of these malignancies share common features, including the expression of either some or all of the EBV latent proteins, which can be potentially exploited for immune-based therapies. Here we discuss new and emerging strategies to manipulate the immune response to specifically boost T-cell immunity towards viral proteins that are expressed in EBV-associated malignancies. These strategies are used either alone or as an adjuvant therapy in combination with chemotherapy and/or monoclonal antibodies. Overall, this strategy may serve as a new paradigm for the successful multi-modality treatment of malignancies.
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Microorganisms in Medicine and Therapeutics
Inhibitors of Viral Protein Synthesis

